In an observational study on Bharat Biotech's Covaxin, nearly a third of participants reported adverse events of special interest (AESI), with females and those with allergies at higher risk. The majority of AESIs persisted at the 1-year follow-up. Common AESIs included viral upper respiratory tract infections, skin disorders, and nervous system issues. Serious AESIs like stroke and Guillain-Barre Syndrome were rare but reported. Females, adolescents, and those with pre-vaccination Covid-19 or comorbidities had higher odds of AESIs. Extended surveillance is recommended to understand late-onset adverse events.